Isomorphic Labs, the Alphabet-owned AI drug discovery company built on the legacy of DeepMind’s AlphaFold research, announced on May 12, 2026 that it had raised $2.1 billion in Series B funding, according to a company press release and reporting from Forbes and BioSpace. The round, led by Thrive Capital, is among the largest single financings any AI-first drug discovery company has ever closed and comes roughly a year after the company raised $600 million from Thrive in early 2025.
Who’s backing the bet
The new round drew participation from existing investors Alphabet and GV, alongside a slate of new backers including MGX, Temasek, CapitalG, and the UK’s Sovereign AI Fund, according to the company’s announcement. That investor mix, spanning US venture money, Gulf sovereign capital, and a UK government-linked fund, signals how far AI drug discovery has moved from a niche academic pursuit into a mainstream, geopolitically significant asset class. Isomorphic Labs said the capital will fund continued development and deployment of its AI drug design engine, internally called IsoDDE, and will help expand its pipeline of therapeutic programs toward clinical testing.
From AlphaFold to the clinic
Isomorphic Labs was spun out of Google DeepMind in 2021 to commercialize the protein-structure-prediction breakthroughs behind AlphaFold, applying similar machine-learning techniques to the much harder problem of designing new drug molecules rather than just predicting how existing proteins fold. The company has built partnerships with major pharmaceutical players including Novartis, Eli Lilly, and Johnson and Johnson, using its models to search chemical space for candidate compounds far faster than traditional wet-lab screening allows. Industry trackers cited by New Market Pitch estimate that Isomorphic Labs and rival Chai Discovery together accounted for roughly 95% of the $2.64 billion in disclosed AI drug discovery financing between March and July of 2026, underscoring how concentrated capital has become in a handful of well-funded players.
The timeline keeps slipping, and that’s the real test
Perhaps the most consequential detail in the announcement is what it reveals about timing. Industry reports referenced by Forbes now put Isomorphic Labs’ first human clinical trials at late 2026, a later date than the company’s own earlier guidance, which had pointed toward the end of 2025. That slippage matters because it is the clearest evidence yet of the gap between what AI models can generate on a computer screen and what actually survives the slower, heavily regulated process of getting a novel compound into a first-in-human study. Skeptics of the AI drug discovery boom, including some computational biologists who have publicly questioned inflated claims about AI-designed drugs, argue that raising billions before a single AI-originated molecule has cleared human trials is a bet on potential rather than proof.
A crowded and increasingly expensive field
Isomorphic Labs is not alone in chasing this model. Chai Discovery, Recursion Pharmaceuticals, and Insilico Medicine have all raised significant capital on similar theses, and analysts at HealthCare Recruiters International have described 2026 as a year of bigger checks, higher expectations, and a tighter talent market for AI drug discovery specifically. That talent competition is itself a bottleneck: the same small pool of machine-learning researchers with biology expertise is being recruited across Isomorphic Labs, Chai Discovery, and pharma-internal AI teams, driving up compensation and, by extension, burn rates at even well-capitalized startups.
What happens if the trials don’t pan out
The next 12 to 18 months will be a genuine test of the AI drug discovery thesis at scale. If Isomorphic Labs’ late-2026 clinical trials succeed, or even generate promising early safety data, it would validate the argument that AI-generated molecules can move faster through the pipeline than conventionally discovered compounds, supporting valuations across the sector. If the trials stall or produce disappointing results, it could sharpen the argument, already voiced by drug-discovery veterans, that AI’s real contribution so far has been accelerating the search for candidates rather than improving the underlying odds that a candidate succeeds in humans, where failure rates for novel compounds have historically exceeded 90%. Either way, Isomorphic Labs’ pharma partners, Novartis, Lilly, and Johnson and Johnson, are watching closely, since their own R&D budgets are increasingly being restructured around the assumption that AI-native discovery will eventually outperform legacy screening methods. For now, the clearest signal of confidence remains the money itself: few sectors outside of large-scale AI infrastructure have attracted a single $2.1 billion round in 2026, and that scale of commitment from Thrive Capital and a slate of sovereign funds suggests investors are pricing in a multi-year runway rather than expecting proof of concept within the next annual cycle.
